Welcome from the Medical & Research Director
The Irish summer is now formally behind us, but there is always hope for a good ol’ “Indian summer”! I recently had the opportunity to attend the European Society of Cardiology meeting in Paris, where it has to be said the weather was delightful.
Major findings reported there related to the use of an antidiabetes medication (dapagliflozin) to successfully treat (and prevent) heart failure even among patients who do not have a diagnosis of diabetes. This is a game-changer and one that has implications for us all and preventive cardiology in particular. Specifically, it reminds us of the importance of preventing and tackling diabetes head on in order to reduce the onslaught of new heart failure diagnoses in our aging population.
Other big news from the ESC meeting included the publication of new cholesterol treatment guidelines that recommended a lower LDL cholesterol target of <1.4 mmol/L for very high risk adults.
In other news, we are now fervently analyzing the iASPIRE data in preparation for the Irish Cardiac Society meeting in Galway in October and the NIPC meeting in Enfield in November. We also had some good news on a couple of other fronts, my colleague Prof David Wood published a review article in The Lancet on the primary prevention of ischemic heart disease that is well worth a read. I did on the plane home from Paris! Furthermore, NIPC was selected for funding from the SlainteCare integration award, which will allow our important myAction programmes to continue running.